The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.

abstract：:This study aims to explore whether E545K, the most common hotspot mutation of PIK3CA in cervical cancer, confers radioresistance to cervical cancer cells, to demonstrate the underling mechanism, and to develop the effective targets. SiHa and MS751 cells with PIK3CA-WT and PIK3CA-E545K were established by lentiviral tr...

journal_title：Molecular cancer therapeutics

authors： Jiang W,Wu Y,He T,Zhu H,Ke G,Xiang L,Yang H

更新日期：2020-02-01 00:00:00

abstract：:Gemcitabine shows a marked antitumor effect as a result of its cytotoxic action toward proliferative cells. In this article, we aim to investigate the potential antitumor and antiangiogenic effect of gemcitabine following a metronomic schedule that involves the regular administration of cytotoxic drugs at doses lower ...

journal_title：Molecular cancer therapeutics

authors： Laquente B,Lacasa C,Ginestà MM,Casanovas O,Figueras A,Galán M,Ribas IG,Germà JR,Capellà G,Viñals F

更新日期：2008-03-01 00:00:00

abstract：:TAS-121 is a novel orally active selective covalent inhibitor of the mutant EGFR. We performed preclinical characterization of TAS-121 and compared its efficacy and selectivity for common EGFR mutations (Ex19del and L858R), first- and second- generation EGFR-tyrosine kinase inhibitor (EGFR-TKI) resistance mutation (T7...

journal_title：Molecular cancer therapeutics

authors： Ito K,Nishio M,Kato M,Murakami H,Aoyagi Y,Ohe Y,Okayama T,Hashimoto A,Ohsawa H,Tanaka G,Nonoshita K,Ito S,Matsuo K,Miyadera K

更新日期：2019-05-01 00:00:00

abstract：:Molecular mechanisms underlying epothilone-induced apoptotic cell death were investigated in SW620 human colon cancer cells. Treatment with epothilone B and D at different concentrations (1-100 nmol/L) dose-dependently inhibited cell growth and caused cell cycle arrest at G2-M, which was followed by apoptosis. Consist...

journal_title：Molecular cancer therapeutics

authors： Lee SH,Son SM,Son DJ,Kim SM,Kim TJ,Song S,Moon DC,Lee HW,Ryu JC,Yoon DY,Hong JT

更新日期：2007-10-01 00:00:00

abstract：:Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively kills tumor cells. However, its short half-life, poor delivery, and TRAIL-resistant tumor cells have diminished its clinical efficacy. In this study, we explored whether novel delivery methods will represent new and effective ways to treat gli...

journal_title：Molecular cancer therapeutics

authors： Hingtgen S,Ren X,Terwilliger E,Classon M,Weissleder R,Shah K

更新日期：2008-11-01 00:00:00

abstract：:The two-step transcriptional activation (TSTA) mechanism in gene therapy amplifies cell type-specific promoter activity, allowing for increased levels of gene expression in target tissues. In this system, the specific promoter drives expression of a strong transcriptional activator that binds to DNA target sequences l...

journal_title：Molecular cancer therapeutics

authors： Arendt ML,Nasir L,Morgan IM

更新日期：2009-12-01 00:00:00

abstract：:Genomic analyses of squamous cell carcinoma (SCC) have yet to yield significant strategies against pathway activation to improve treatment. Platinum-based chemotherapy remains the mainstay of treatment for SCC of different histotypes either as a single-agent or alongside other chemotherapeutic drugs or radiotherapy; h...

journal_title：Molecular cancer therapeutics

authors： Kong LR,Chua KN,Sim WJ,Ng HC,Bi C,Ho J,Nga ME,Pang YH,Ong WR,Soo RA,Huynh H,Chng WJ,Thiery JP,Goh BC

更新日期：2015-07-01 00:00:00

abstract：:The MET receptor tyrosine kinase, the receptor for hepatocyte growth factor (HGF), has been implicated in cancer growth, invasion, migration, angiogenesis, and metastasis in a broad variety of human cancers, including human hepatocellular carcinoma (HCC). Recently, MET was suggested to be a potential target for the pe...

journal_title：Molecular cancer therapeutics

authors： Jo JC,Choi EK,Shin JS,Moon JH,Hong SW,Lee HR,Kim SM,Jung SA,Lee DH,Jung SH,Lee SH,Kim JE,Kim KP,Hong YS,Suh YA,Jang SJ,Choi EK,Lee JS,Jin DH,Kim TW

更新日期：2015-11-01 00:00:00

abstract：:Human epidermal growth factor receptor-2 (HER2) and epidermal growth factor receptor (EGFR) heterodimerize to activate mitogenic signaling pathways. We have shown previously, using MCF7 subcloned cell lines with graded levels of HER2 expression, that responsiveness to trastuzumab and AG1478 (an anti-EGFR agent), varie...

journal_title：Molecular cancer therapeutics

authors： Emlet DR,Brown KA,Kociban DL,Pollice AA,Smith CA,Ong BB,Shackney SE

更新日期：2007-10-01 00:00:00

abstract：:This work is based on previous evidence showing that chemotactic sequence of the urokinase receptor (uPAR(88-92)) drives angiogenesis in vitro and in vivo in a protease-independent manner, and that the peptide Ac-Arg-Glu-Arg-Phe-NH(2) (RERF) prevents both uPAR(88-92)- and VEGF-induced angiogenesis. New N-acetylated an...

journal_title：Molecular cancer therapeutics

authors： Carriero MV,Bifulco K,Minopoli M,Lista L,Maglio O,Mele L,Di Carluccio G,De Rosa M,Pavone V

更新日期：2014-05-01 00:00:00

abstract：:Tumor cells are efficiently killed after incubation with alpha-emitter immunoconjugates targeting tumor-specific antigens. Therefore, application of alpha-emitter immunoconjugates is a promising therapeutic option for treatment of carcinomas that are characterized by dissemination of single tumor cells in the peritone...

journal_title：Molecular cancer therapeutics

authors： Seidl C,Port M,Gilbertz KP,Morgenstern A,Bruchertseifer F,Schwaiger M,Röper B,Senekowitsch-Schmidtke R,Abend M

更新日期：2007-08-01 00:00:00

abstract：:Complexities in treating breast cancer with bone metastasis are enhanced by a vicious protumorigenic pathology, involving a shift in skeletal homeostasis toward aggressive osteoclast activity and polarization of immune cells supporting tumor growth and immunosuppression. Recent studies signify the role of receptor act...

journal_title：Molecular cancer therapeutics

authors： Wang H,Ashton R,Hensel JA,Lee JH,Khattar V,Wang Y,Deshane JS,Ponnazhagan S

更新日期：2020-12-01 00:00:00

abstract：:The traditional maximum dose density chemotherapy renders the tumor patients not only the tumor remission but the chemotherapy resistance and more adverse side effects. According to the widely positive expression of Toll-like receptor (TLR)-3 in oral squamous cell carcinoma (OSCC) patients (n = 166), we here provided ...

journal_title：Molecular cancer therapeutics

authors： Ding L,Ren J,Zhang D,Li Y,Huang X,Ji J,Hu Q,Wang H,Ni Y,Hou Y

更新日期：2017-06-01 00:00:00

abstract：:Neuroblastoma is the most common extracranial solid malignancy in the pediatric population, accounting for over 9% of all cancer-related deaths in children. Autophagy is a cell self-protective mechanism that promotes tumor cell growth and survival, making it an attractive target for treating cancer. However, the role ...

journal_title：Molecular cancer therapeutics

authors： Dower CM,Bhat N,Gebru MT,Chen L,Wills CA,Miller BA,Wang HG

更新日期：2018-11-01 00:00:00

abstract：:Nucleoside phosphonates are widely used therapeutic agents with a broad spectrum of antiviral activity. However, only a few of them are reported to have antitumor activity. In this study, we show that a tetrahydrofuran phosphonate analogue of guanosine, (-)-2-R-dihydroxyphosphinoyl-5-(S)-(guanin-9'-ylmethyl) tetrahydr...

journal_title：Molecular cancer therapeutics

authors： Leblond L,Attardo G,Hamelin B,Bouffard DY,Nguyen-Ba N,Gourdeau H

更新日期：2002-07-01 00:00:00

abstract：:17β-Hydroxysteroid dehydrogenase type 1 (17β-HSD1) converts estrone (E1) into estradiol (E2) and is expressed in many steroidogenic tissues and breast cancer cell lines. Because the potent estrogen E2 stimulates the growth and development of hormone-dependent diseases, inhibition of the final step of E2 synthesis is c...

journal_title：Molecular cancer therapeutics

authors： Ayan D,Maltais R,Roy J,Poirier D

更新日期：2012-10-01 00:00:00

abstract：:We discovered a thalidomide analogue [5-hydroxy-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33)] with antiproliferative activity against nine cancer cell lines in vitro. Flow cytometric analyses showed that the compound caused G2-M arrest, which occurred mainly at the mitotic phase. In addition, immunofluores...

journal_title：Molecular cancer therapeutics

authors： Li PK,Pandit B,Sackett DL,Hu Z,Zink J,Zhi J,Freeman D,Robey RW,Werbovetz K,Lewis A,Li C

更新日期：2006-02-01 00:00:00

abstract：:Gallium nitrate is a metallodrug with clinical efficacy in non-Hodgkin's lymphoma. Its mechanisms of antineoplastic action are not fully understood. In the present study, we investigated the roles of transferrin receptor (TfR) targeting and apoptotic pathways in gallium-induced cell death. Although DoHH2 lymphoma cell...

journal_title：Molecular cancer therapeutics

authors： Chitambar CR,Wereley JP,Matsuyama S

更新日期：2006-11-01 00:00:00

abstract：:Mis-expression of microRNAs (miRNA) is widespread in human cancers, including in pancreatic cancer. Aberrations of miRNA include overexpression of oncogenic miRs (Onco-miRs) or downregulation of so-called tumor suppressor TSG-miRs. Restitution of TSG-miRs in cancer cells through systemic delivery is a promising avenue...

journal_title：Molecular cancer therapeutics

authors： Pramanik D,Campbell NR,Karikari C,Chivukula R,Kent OA,Mendell JT,Maitra A

更新日期：2011-08-01 00:00:00

abstract：:Pancreatic ductal adenocarcinoma (PDAC) is one of the most chemotherapy- and radiotherapy-resistant tumors. The c-Met and Hedgehog (Hh) pathways have been shown previously by our group to be key regulatory pathways in the primary tumor growth and metastases formation. Targeting both the HGF/c-Met and Hh pathways has s...

journal_title：Molecular cancer therapeutics

authors： Rucki AA,Xiao Q,Muth S,Chen J,Che X,Kleponis J,Sharma R,Anders RA,Jaffee EM,Zheng L

更新日期：2017-11-01 00:00:00

abstract：:Previous studies have shown a statistically significant correlation between human carcinomas and monoclonal antibody detection of a Mycoplasma hyorhinis-encoded protein known as p37. A potential mechanism of p37 is that it might promote invasion and metastasis. Recombinant p37 enhanced the invasiveness of two prostate...

journal_title：Molecular cancer therapeutics

authors： Ketcham CM,Anai S,Reutzel R,Sheng S,Schuster SM,Brenes RB,Agbandje-McKenna M,McKenna R,Rosser CJ,Boehlein SK

更新日期：2005-07-01 00:00:00

abstract：:The inverse association between a high enterolactone (ENL) concentration in both urine and serum, and the risk of breast cancer found in epidemiological studies suggests a chemopreventive action for ENL. However, no causal relationship has been established in clinical studies or in experimental models for breast cance...

journal_title：Molecular cancer therapeutics

authors： Saarinen NM,Huovinen R,Wärri A,Mäkelä SI,Valentín-Blasini L,Sjöholm R,Ammälä J,Lehtilä R,Eckerman C,Collan YU,Santti RS

更新日期：2002-08-01 00:00:00

abstract：:Controversy exists surrounding whether heterogeneous disruption of the blood-brain barrier (BBB), as seen in glioblastoma (GBM), leads to adequate drug delivery sufficient for efficacy in GBM. This question is especially important when using potent, targeted agents that have a poor penetration across an intact BBB. Ef...

journal_title：Molecular cancer therapeutics

authors： Kim M,Ma DJ,Calligaris D,Zhang S,Feathers RW,Vaubel RA,Meaux I,Mladek AC,Parrish KE,Jin F,Barriere C,Debussche L,Watters J,Tian S,Decker PA,Eckel-Passow JE,Kitange GJ,Johnson AJ,Parney IF,Anastasiadis PZ,Agar NYR

更新日期：2018-09-01 00:00:00

abstract：:The emergence of drug resistance is often an inevitable obstacle that limits the long-term effectiveness of clinical cancer chemotherapeutics. Although various forms of cancer cell-intrinsic mechanisms of drug resistance have been experimentally revealed, the role and the underlying mechanism of tumor microenvironment...

journal_title：Molecular cancer therapeutics

authors： Zheng Y,Bao J,Zhao Q,Zhou T,Sun X

更新日期：2018-04-01 00:00:00

abstract：:Labetuzumab govitecan (IMMU-130), an antibody-drug conjugate (ADC) with an average of 7.6 SN-38/IgG, was evaluated for its potential to enhance delivery of SN-38 to human colonic tumor xenografts. Mice bearing LS174T or GW-39 human colonic tumor xenografts were injected with irinotecan or IMMU-130 (SN-38 equivalents ∼...

journal_title：Molecular cancer therapeutics

authors： Sharkey RM,Govindan SV,Cardillo TM,Donnell J,Xia J,Rossi EA,Chang CH,Goldenberg DM

更新日期：2018-01-01 00:00:00

abstract：:The phosphatidylinositol 3-kinase (PI3K)/Akt pathway is known to be activated by radiation. The mammalian target of rapamycin (mTOR) is downstream of Akt, and we investigated the effects of radiation on Akt/mTOR signaling in breast cancer cell models. RAD001 (everolimus), a potent derivative of the mTOR inhibitor rapa...

journal_title：Molecular cancer therapeutics

authors： Albert JM,Kim KW,Cao C,Lu B

更新日期：2006-05-01 00:00:00

abstract：:Trastuzumab and the related ADC, ado-trastuzumab emtansine (T-DM1), both target HER2-overexpressing cells. Together, these drugs have treatment indications in both early-stage and metastatic settings for HER2+ breast cancer. T-DM1 retains the antibody functionalities of trastuzumab and adds the potency of a cytotoxic ...

journal_title：Molecular cancer therapeutics

authors： Barfield RM,Kim YC,Chuprakov S,Zhang F,Bauzon M,Ogunkoya AO,Yeo D,Hickle C,Pegram MD,Rabuka D,Drake PM

更新日期：2020-09-01 00:00:00

abstract：:Repurposing cationic amphiphilic drugs (CAD) for cancer treatment is emerging as an attractive means to enhance the efficacy of chemotherapy. Many commonly used CADs, including several cation amphiphilic antihistamines and antidepressants, induce cancer-specific, lysosome-dependent cell death and sensitize cancer cell...

journal_title：Molecular cancer therapeutics

authors： Anand A,Liu B,Dicroce Giacobini J,Maeda K,Rohde M,Jäättelä M

更新日期：2019-09-01 00:00:00

abstract：:Cetuximab, an antibody against the EGFR, has shown efficacy in treating head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer, and non-small cell lung cancer (NSCLC). Despite the clinical success of cetuximab, many patients do not respond to cetuximab. Furthermore, virtually all patients who do i...

journal_title：Molecular cancer therapeutics

authors： Iida M,Bahrar H,Brand TM,Pearson HE,Coan JP,Orbuch RA,Flanigan BG,Swick AD,Prabakaran PJ,Lantto J,Horak ID,Kragh M,Salgia R,Kimple RJ,Wheeler DL

更新日期：2016-09-01 00:00:00

abstract：:Bladder cancer is a common human malignancy. Conventional ultrasound and white-light cystoscopy are often used for bladder cancer diagnosis and resection, but insufficient specificity results in a high bladder cancer recurrence rate. New strategies for the diagnosis and resection of bladder cancer are needed. In this ...

journal_title：Molecular cancer therapeutics

authors： Peng L,Shang W,Guo P,He K,Wang H,Han Z,Jiang H,Tian J,Wang K,Xu W

更新日期：2018-10-01 00:00:00